Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.38% | -50.35% | -2.91% | -32.65% | 25.67% |
| Total Depreciation and Amortization | 0.00% | 2.33% | 79.17% | 26.32% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.29% | 28.99% | 28.75% | 5.18% | 3.18% |
| Change in Net Operating Assets | -80.03% | 44.40% | 166.90% | 264.06% | -137.57% |
| Cash from Operations | -17.86% | -57.03% | 18.33% | -14.28% | 8.94% |
| Capital Expenditure | 0.00% | 74.79% | -466.67% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -283.10% | 223.03% | 65.23% | -- | -- |
| Cash from Investing | -283.27% | 222.60% | 65.13% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.57% | 423.04% | 7,062.84% | 222.96% | -70.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.57% | 423.04% | 7,062.84% | 222.96% | -70.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -200.04% | 402.42% | 71.70% | -940.63% | 7.91% |